Literature DB >> 34529196

The WISDOM study: a new approach to screening can and should be tested.

Laura Esserman1, Martin Eklund2, Laura Van't Veer3, Yiwey Shieh3, Jeffrey Tice3, Elad Ziv3, Amie Blanco3, Celia Kaplan3, Robert Hiatt3, Allison Stover Fiscalini3, Christina Yau3, Maren Scheuner3, Arash Naeim4, Neil Wenger4, Vivian Lee3, Diane Heditsian3, Susie Brain3, Barbara A Parker5, Andrea Z LaCroix5, Lisa Madlensky5, Michael Hogarth5, Alexander Borowsky6, Hoda Anton-Culver7, Andrea Kaster8, Olufunmilayo I Olopade9, Deepa Sheth9, Augustin Garcia10, Rachael Lancaster11, Michael Plaza12.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34529196     DOI： 10.1007/s10549-021-06346-w

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


× No keyword cloud information.
  20 in total

1.  Surgical vs nonoperative treatment for lumbar disk herniation: the Spine Patient Outcomes Research Trial (SPORT) observational cohort.

Authors:  James N Weinstein; Jon D Lurie; Tor D Tosteson; Jonathan S Skinner; Brett Hanscom; Anna N A Tosteson; Harry Herkowitz; Jeffrey Fischgrund; Frank P Cammisa; Todd Albert; Richard A Deyo
Journal:  JAMA       Date:  2006-11-22       Impact factor: 56.272

2.  Surgical vs nonoperative treatment for lumbar disk herniation: the Spine Patient Outcomes Research Trial (SPORT): a randomized trial.

Authors:  James N Weinstein; Tor D Tosteson; Jon D Lurie; Anna N A Tosteson; Brett Hanscom; Jonathan S Skinner; William A Abdu; Alan S Hilibrand; Scott D Boden; Richard A Deyo
Journal:  JAMA       Date:  2006-11-22       Impact factor: 56.272

3.  Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement.

Authors:  Albert L Siu
Journal:  Ann Intern Med       Date:  2016-01-12       Impact factor: 25.391

4.  Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Authors:  Hope S Rugo; Olufunmilayo I Olopade; Angela DeMichele; Christina Yau; Laura J van 't Veer; Meredith B Buxton; Michael Hogarth; Nola M Hylton; Melissa Paoloni; Jane Perlmutter; W Fraser Symmans; Douglas Yee; A Jo Chien; Anne M Wallace; Henry G Kaplan; Judy C Boughey; Tufia C Haddad; Kathy S Albain; Minetta C Liu; Claudine Isaacs; Qamar J Khan; Julie E Lang; Rebecca K Viscusi; Lajos Pusztai; Stacy L Moulder; Stephen Y Chui; Kathleen A Kemmer; Anthony D Elias; Kirsten K Edmiston; David M Euhus; Barbara B Haley; Rita Nanda; Donald W Northfelt; Debasish Tripathy; William C Wood; Cheryl Ewing; Richard Schwab; Julia Lyandres; Sarah E Davis; Gillian L Hirst; Ashish Sanil; Donald A Berry; Laura J Esserman
Journal:  N Engl J Med       Date:  2016-07-07       Impact factor: 91.245

5.  Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.

Authors:  Rita Nanda; Minetta C Liu; Christina Yau; Rebecca Shatsky; Lajos Pusztai; Anne Wallace; A Jo Chien; Andres Forero-Torres; Erin Ellis; Heather Han; Amy Clark; Kathy Albain; Judy C Boughey; Nora T Jaskowiak; Anthony Elias; Claudine Isaacs; Kathleen Kemmer; Teresa Helsten; Melanie Majure; Erica Stringer-Reasor; Catherine Parker; Marie C Lee; Tufia Haddad; Ronald N Cohen; Smita Asare; Amy Wilson; Gillian L Hirst; Ruby Singhrao; Katherine Steeg; Adam Asare; Jeffrey B Matthews; Scott Berry; Ashish Sanil; Richard Schwab; W Fraser Symmans; Laura van 't Veer; Douglas Yee; Angela DeMichele; Nola M Hylton; Michelle Melisko; Jane Perlmutter; Hope S Rugo; Donald A Berry; Laura J Esserman
Journal:  JAMA Oncol       Date:  2020-05-01       Impact factor: 31.777

6.  Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).

Authors:  Cheryl Lin; Meredith Becker Buxton; Dan Moore; Helen Krontiras; Lisa Carey; Angela DeMichele; Leslie Montgomery; Debasish Tripathy; Constance Lehman; Minetta Liu; Olufunmilayo Olapade; Christina Yau; Donald Berry; Laura J Esserman
Journal:  Breast Cancer Res Treat       Date:  2011-07-28       Impact factor: 4.872

Review 7.  The WISDOM Study: breaking the deadlock in the breast cancer screening debate.

Authors:  Laura J Esserman
Journal:  NPJ Breast Cancer       Date:  2017-09-13

8.  Partially randomised patient preference trials as an alternative design to randomised controlled trials: systematic review and meta-analyses.

Authors:  Karin A Wasmann; Pieta Wijsman; Susan van Dieren; Willem Bemelman; Christianne Buskens
Journal:  BMJ Open       Date:  2019-10-16       Impact factor: 2.692

9.  Recommendations From Breast Cancer Centers for Frequent Screening Mammography in Younger Women May Do More Harm Than Good.

Authors:  Anand R Habib; Deborah Grady; Rita F Redberg
Journal:  JAMA Intern Med       Date:  2021-05-01       Impact factor: 21.873

10.  Assessment of Screening Mammography Recommendations by Breast Cancer Centers in the US.

Authors:  Neal S Patel; Mark Lee; Jennifer L Marti
Journal:  JAMA Intern Med       Date:  2021-05-01       Impact factor: 21.873
View more
  4 in total

1.  Screening MRI in Patients with High-Risk Breast Lesions: More May Not Necessarily be More.

Authors:  Juan C Paramo; Roshni Rao
Journal:  Ann Surg Oncol       Date:  2022-09-25       Impact factor: 4.339

2.  Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the "My Personal Breast Screening" (MyPeBS) randomised clinical trial.

Authors:  Alexandra Roux; Rachel Cholerton; Jonathan Sicsic; Nora Moumjid; David P French; Paolo Giorgi Rossi; Corinne Balleyguier; Michal Guindy; Fiona J Gilbert; Jean-Benoit Burrion; Xavier Castells; David Ritchie; Debbie Keatley; Camille Baron; Suzette Delaloge; Sandrine de Montgolfier
Journal:  BMC Cancer       Date:  2022-05-06       Impact factor: 4.638

3.  Personalized Approaches for the Prevention and Treatment of Breast Cancer.

Authors:  Hermann Nabi
Journal:  J Pers Med       Date:  2022-07-23

4.  Healthcare professionals' views following implementation of risk stratification into a national breast cancer screening programme.

Authors:  Rachel Hawkins; Lorna McWilliams; Fiona Ulph; D Gareth Evans; David P French
Journal:  BMC Cancer       Date:  2022-10-12       Impact factor: 4.638
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.